Key facts
- This page summarizes Timothy Eugene Sullivan's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 6 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jun 2023, 16:59.
Timothy Eugene Sullivan - 05 Jun 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- APLS
- Reported as of
- 05 Jun 2023
- Net transaction value
- -$5,496,643
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2023, 16:59:30 UTC
- Prior SEC filing
- 03 May 2023
- Next SEC filing
- 06 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/s David Watson, attorney-in-fact for Timothy Sullivan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Timothy Eugene Sullivan filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 06 Jun 2023.
Change
- Previous filing in this sequence was filed on 03 May 2023.
- Current net transaction value: -$5,496,643.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Options Exercise
- Transaction value
- $699,883
- Shares
- +69,779
- Change %
- +90%
- Price
- $10.03
- Shares after
- 147,492
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
APLS
transaction
Common Stock
Sale
- Transaction value
- $144,967
- Shares
- -1,600
- Change %
- -1.1%
- Price
- $90.60
- Shares after
- 145,892
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2, F3
APLS
transaction
Common Stock
Sale
- Transaction value
- $2,687,121
- Shares
- -30,609
- Change %
- -21%
- Price
- $87.79
- Shares after
- 115,283
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2, F4
APLS
transaction
Common Stock
Sale
- Transaction value
- $624,210
- Shares
- -7,064
- Change %
- -6.1%
- Price
- $88.36
- Shares after
- 108,219
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2, F5
APLS
transaction
Common Stock
Sale
- Transaction value
- $2,740,229
- Shares
- -30,506
- Change %
- -28%
- Price
- $89.83
- Shares after
- 77,713
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2, F6
APLS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 56,232
- Date
- 05 Jun 2023
- Ownership
- The Timothy E Sullivan Irrevocable Trust of 2023
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -69,779
- Change %
- -19%
- Price
- $0.000000
- Shares after
- 288,840
- Date
- 05 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,779
- Exercise price
- $10.03
- Footnotes
- F2, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
Footnote F2
This is a scheduled exercise & sale from 10b5-1 trading plan.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $90.380 - $90.790. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F4
This transaction was executed in multiple trades at prices ranging from $87.155 - $88.150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F5
This transaction was executed in multiple trades at prices ranging from $88.160 - $89.130. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F6
This transaction was executed in multiple trades at prices ranging from $89.375 - $90.370. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F7
This option was granted on October 18, 2017 and fully vested.